Pulmonary Disease Doctors in Eastchester, NY Accepting Medicare

5 Pulmonary Disease doctors found. Showing 1 - 5

Farhad Arjomand, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 329 White Plains Rd Ste 100, Eastchester, NY 10709 Phone: 914-337-1610    Fax: 914-337-9312

Thaofiq Olatunde Ijaiya, Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 329 White Plains Rd Ste 100, Eastchester, NY 10709 Phone: 914-337-1610    Fax: 914-337-9312

Dr. Miroslav Nudelman, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 329 White Plains Road, Eastchester, NY 10709 Phone: 914-337-1610    Fax: 914-337-9312

Dr. Michael J Morelli, MD Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 329 White Plains Road, Eastchester, NY 10709 Phone: 914-337-1610    Fax: 914-337-9312

Dr. Ralph E Binder, MD Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 329 White Plains Road, Eastchester, NY 10709 Phone: 914-337-1610    Fax: 914-337-9312

News Archive

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies.

DMP1 protein prevents endothelial cells to respond to VEGF

A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout.

Patients with hearing, vision and speech disabilities to be provided with auxiliary aids and services

Patients with hearing, vision, and speech disabilities, who receive care at University of Utah Hospitals & Clinics, will be screened and provided with auxiliary aids and services as required by federal law under a Resolution Agreement reached with the U.S. Department of Health and Human Services (HHS).

Read more Medical News

› Verified 8 days ago